JP MORGAN 2015: Roche in dealmaking mode for antibiotics, diagnostics
This article was originally published in Scrip
Roche told Scrip on 12 January during the 33rd Annual JP Morgan Healthcare Conference in San Francisco that the company is actively looking to do deals in oncology, neurology and infectious diseases and by the end of the day unveiled a new licensing deal for a Phase I antibiotic.
You may also be interested in...
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.